TABLE 4.

Multivariable polytomous regression models of prescription contraceptive prevalence among women by cohort year, HIV infection status, and antiretroviral therapy use

	Female sterilization		LARC		SAHC
	OR (95% CI)	aOR (95% CI)	OR (95% CI)	aOR (95% CI)	OR (95% CI)	aOR (95% CI)
HIV infected vs noninfecteda,b	1.28 (0.99–1.67)	0.83 (0.64–1.08)	0.82 (0.64–1.05)	0.67 (0.52–0.86)	0.49 (0.41–0.57)	0.59 (0.50–0.70)
ART use vs nonusec	0.99 (0.58–1.68)	0.95 (0.56–1.61)	0.63 (0.38–1.05)	0.68 (0.41–1.13)	0.41 (0.29–0.56)	0.45 (0.32–0.63)
2014 vs 2008b	1.12 (1.10–1.14)	1.21 (1.19–1.23)	3.19 (3.13–3.25)	3.35 (3.29–3.42)	1.54 (1.53–1.55)	1.44 (1.43–1.45)

Polytomous model 4 contraceptive groups where referent group is no prescription method use. No prescription method includes women with no contraceptive codes; these may have included women using nonprescription methods, such as condoms.

aOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; LARC, long-acting reversible contraception including intrauterine devices and implants; OR, odds ratio; SAHC, short-acting hormonal contraception includes contraceptive pills, patches, rings, and injectable methods.

^aART, considered only for those who are HIV infected;

^bAdjusted for year, any chronic medical condition, age category, region, pregnancy;

^cAdjusted for year, age category.